Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90

被引:160
作者
He, HZ
Zatorska, D
Kim, J
Aguirre, J
Llauger, L
She, YH
Wu, N
Immormino, RM
Gewirth, DT
Chiosis, G
机构
[1] Mem Sloan Kettering Canc Ctr, Program Mol Pharmacol & Chem, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
关键词
D O I
10.1021/jm0508078
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Hsp90 is a chaperone protein that allows cancer cells to tolerate the many components of dysregulated pathways. Its inactivation may result in targeting multiple molecular alterations and, thus, in reverting the transformed phenotype. The PU-class, a purine-scaffold Hsp90 inhibitor series, has been reported to be potent and selective against Hsp90 both in vitro and in vivo models of cancer. Here, a series of this class was synthesized and evaluated as inhibitors of the chaperone. The structure-activity relationship and selectivity for tumor Hsp90 of compounds within the series is presented. The study identifies water soluble derivatives (> 5 mM in PBS pH 7.4) of nanomolar potency (IC50 similar to 50 nM) in cellular and animal models of cancer. Binding affinities of these compounds for Hsp90 correlate well with their biological activities. When administered in vivo to mice bearing MDA-MB-468 human breast cancer xenocyrafted tumors, these agents result in pharmacologically relevant concentrations and, accordingly, in modulation of Hsp90-client proteins in tumors.
引用
收藏
页码:381 / 390
页数:10
相关论文
共 45 条
[1]   Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models [J].
Banerji, U ;
Walton, M ;
Raynaud, F ;
Grimshaw, R ;
Kelland, L ;
Valenti, M ;
Judson, I ;
Workman, P .
CLINICAL CANCER RESEARCH, 2005, 11 (19) :7023-7032
[2]   Mild and regioselective iodination of electron-rich aromatics with N-iodosuccinimide and catalytic trifluoroacetic acid [J].
Castanet, AS ;
Colobert, F ;
Broutin, PE .
TETRAHEDRON LETTERS, 2002, 43 (29) :5047-5048
[3]   ATPases as drug targets:: Learning from their structure [J].
Chène, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (09) :665-673
[4]   Hsp90: the vulnerable chaperone [J].
Chiosis, G ;
Vilenchik, M ;
Kim, J ;
Solit, D .
DRUG DISCOVERY TODAY, 2004, 9 (20) :881-888
[5]   A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells [J].
Chiosis, G ;
Timaul, MN ;
Lucas, B ;
Munster, PN ;
Zheng, FF ;
Sepp-Lorenzino, L ;
Rosen, N .
CHEMISTRY & BIOLOGY, 2001, 8 (03) :289-299
[6]   Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase [J].
Chiosis, G ;
Lucas, B ;
Shtil, A ;
Huezo, H ;
Rosen, N .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (11) :3555-3564
[7]  
CHIOSIS G, 2005, Patent No. 2005012482
[8]  
CHIOSIS G, 2002, Patent No. 20020236075
[9]   Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90 [J].
Chiosis, Gabriela ;
Lucas, Brian ;
Huezo, Henri ;
Solit, David ;
Basso, Andrea ;
Rosen, Neal .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :371-376
[10]  
Day RA, 2003, SYNTHESIS-STUTTGART, P1586